Compare RH & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RH | GHRS |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2011 | 2021 |
| Metric | RH | GHRS |
|---|---|---|
| Price | $133.78 | $19.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 10 |
| Target Price | ★ $164.41 | $42.89 |
| AVG Volume (30 Days) | ★ 752.4K | 323.5K |
| Earning Date | 12-10-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.31 | N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,193,046,000.00 | N/A |
| Revenue This Year | $5.68 | N/A |
| Revenue Next Year | $9.26 | N/A |
| P/E Ratio | $57.18 | ★ N/A |
| Revenue Growth | ★ 24.52 | N/A |
| 52 Week Low | $106.30 | $12.04 |
| 52 Week High | $239.40 | $31.44 |
| Indicator | RH | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 50.18 | 43.18 |
| Support Level | $123.55 | $17.54 |
| Resistance Level | $137.90 | $22.51 |
| Average True Range (ATR) | 8.20 | 1.26 |
| MACD | -0.28 | 0.18 |
| Stochastic Oscillator | 30.36 | 41.50 |
RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and has a growing presence in hospitality with 27 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across design subcategories (RH Estates and Waterworks, for example), and has recently broadened its addressable market via expansion abroad (currently, less than 10% of sales) and its World of RH digital platform (highlighting offerings outside of home furnishings).
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.